Institution
Eli Lilly and Company
Company•Indianapolis, Indiana, United States•
About: Eli Lilly and Company is a company organization based out in Indianapolis, Indiana, United States. It is known for research contribution in the topics: Population & Receptor. The organization has 17826 authors who have published 22835 publications receiving 946714 citations. The organization is also known as: Eli Lily.
Topics: Population, Receptor, Placebo, Insulin, Agonist
Papers published on a yearly basis
Papers
More filters
TL;DR: It is demonstrated that the sphingolipid ceramide is a common molecular intermediate linking several different pathological metabolic stresses to the induction of insulin resistance, and enzymes required for ceramide synthesis are identified as therapeutic targets for combating insulin resistance caused by nutrient excess or glucocorticoid therapy.
1,105 citations
TL;DR: The evolution of pharmacological agents that have been reported to target mGlu receptors are reviewed, with a focus on the known receptor subtype selectivities of current agents.
1,103 citations
TL;DR: In this interim analysis of a phase 2 trial, one of three doses of neutralizing antibody LY-CoV555 appeared to accelerate the natural decline in viral load over time, whereas the other doses had not by day 11.
Abstract: Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (Covid-19), which is most frequently mild yet can be severe and life-threatening. Vi...
1,081 citations
TL;DR: Maintenance therapy with pemetrexed is well tolerated and offers improved progression-free and overall survival compared with placebo in patients with advanced non-small-cell lung cancer.
1,070 citations
TL;DR: Asymptomatic persons 50 years of age or older who have polyps in the distal colon are more likely to have advanced proximal neoplasia than are persons without distal polyps, and older age and male sex were associated with an increased risk.
Abstract: Background and Methods The clinical significance of a distal colorectal polyp is uncertain. We determined the risk of advanced proximal neoplasia, defined as a polyp with villous features, a polyp with high-grade dysplasia, or cancer, among persons with distal hyperplastic or neoplastic polyps as compared with the risk among persons with no distal polyps. We analyzed data from 1994 consecutive asymptomatic adults (age, 50 years or older) who underwent colonoscopic screening for the first time between September 1995 and December 1998 as part of a program sponsored by an employer. The location and histologic features of all polyps were recorded. Colonoscopy to the level of the cecum was completed in 97.0 percent of the patients. Results Sixty-one patients (3.1 percent) had advanced lesions in the distal colon, including 5 with cancer, and 50 (2.5 percent) had advanced proximal lesions, including 7 with cancer. Twenty-three patients with advanced proximal neoplasms (46 percent) had no distal polyps. The prev...
1,064 citations
Authors
Showing all 17866 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Mark J. Daly | 204 | 763 | 304452 |
| Irving L. Weissman | 201 | 1141 | 172504 |
| Eric J. Topol | 193 | 1373 | 151025 |
| Tony Hunter | 175 | 593 | 124726 |
| Xiang Zhang | 154 | 1733 | 117576 |
| Jerrold M. Olefsky | 143 | 595 | 77356 |
| Stephen F. Badylak | 133 | 530 | 57083 |
| George A. Bray | 131 | 896 | 100975 |
| Lloyd Paul Aiello | 131 | 506 | 85550 |
| Levi A. Garraway | 129 | 366 | 99989 |
| Mark Sullivan | 126 | 802 | 63916 |
| James A. Russell | 124 | 1024 | 87929 |
| Tony L. Yaksh | 123 | 806 | 60898 |
| Elisabetta Dejana | 122 | 430 | 48254 |
| Hagop S. Akiskal | 118 | 565 | 50869 |